JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
ConditionSolid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJacobio Pharmaceuticals Co., Ltd.
About this trial
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Eligibility criteria
Qualifiers
Written informed consent.
Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
ECOG performance status score of 0 or 1.
Has been treated with at least one line of systemic therapy for that tumor type and stage.
Disqualifiers
Active brain or spinal metastases or primary CNS tumor.
Active infection requiring systemic treatment within 7 days.
Active HBV or HCV.
Any severe and/or uncontrolled medical conditions.
Trial design
Treatments tested in this trial
- JAB-30355
- JAB-30355
Treatment groups
144 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov